Agenus (AJ8) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Zalifrelimab, Evofosfamide, Balstilimab | Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Head And Neck Squamous Cell Carcinoma | phase1AndPhase2 | Recruiting | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Jan 09, 2025 | ― |
| Gemcitabine, Nab-paclitaxel, Botensilimab | Metastatic Pancreatic Ductal Adenocarcinoma | Phase II | Active Not Recruiting | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Nov 18, 2022 | ― |
| Standard of Care, Botensilimab, Balstilimab | Metastatic Colorectal Cancer | Phase II | Active Not Recruiting | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Nov 01, 2022 | ― |
| Botensilimab, Balstilimab | Advanced Melanoma | Phase II | Active Not Recruiting | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Sep 02, 2022 | ― |
| Botensilimab, Balstilimab, Agen1571 | Advanced Solid Tumor | Phase I | Completed | Study of AGEN1571 in Participants With Advanced Solid Tumors | May 12, 2022 | ― |
| Agen2034, Cr6086 | Solid Tumor, Gastric Cancer, Refractory Metastatic Colorectal Cancer, Metastatic Microsatellite-Stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic Gi Cancers | phase1AndPhase2 | Recruiting | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Jan 20, 2022 | ― |
| Agen1777, A Pd-1 Inhibitor | Advanced Cancer | Phase I | Completed | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Aug 10, 2021 | ― |
| Gemcitabine, Nab Paclitaxel, Nlm-001, Zalifrelimab | Pancreatic Ductal Adenocarcinoma | phase1AndPhase2 | Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | Mar 30, 2021 | ― |
| Botensilimab, Agen2373 | Advanced Cancer | Phase I | Completed | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | Oct 02, 2019 | ― |
| Agen2034, Agen1884 | Cervical Cancer | Phase II | Active Not Recruiting | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Mar 19, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Zalifrelimab, Evofosfamide, Balstilimab | phase1AndPhase2 | Metastatic Pancreatic Cancer, Metastatic Prostate Cancer, Metastatic Head And Neck Squamous Cell Carcinoma | Recruiting | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | Jan 09, 2025 | ― |
| Gemcitabine, Nab-paclitaxel, Botensilimab | Phase II | Metastatic Pancreatic Ductal Adenocarcinoma | Active Not Recruiting | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Nov 18, 2022 | ― |
| Standard of Care, Botensilimab, Balstilimab | Phase II | Metastatic Colorectal Cancer | Active Not Recruiting | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Nov 01, 2022 | ― |
| Botensilimab, Balstilimab | Phase II | Advanced Melanoma | Active Not Recruiting | A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma | Sep 02, 2022 | ― |
| Botensilimab, Balstilimab, Agen1571 | Phase I | Advanced Solid Tumor | Completed | Study of AGEN1571 in Participants With Advanced Solid Tumors | May 12, 2022 | ― |
| Agen2034, Cr6086 | phase1AndPhase2 | Solid Tumor, Gastric Cancer, Refractory Metastatic Colorectal Cancer, Metastatic Microsatellite-Stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic Gi Cancers | Recruiting | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | Jan 20, 2022 | ― |
| Agen1777, A Pd-1 Inhibitor | Phase I | Advanced Cancer | Completed | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors | Aug 10, 2021 | ― |
| Gemcitabine, Nab Paclitaxel, Nlm-001, Zalifrelimab | phase1AndPhase2 | Pancreatic Ductal Adenocarcinoma | Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer | Mar 30, 2021 | ― |
| Botensilimab, Agen2373 | Phase I | Advanced Cancer | Completed | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer | Oct 02, 2019 | ― |
| Agen2034, Agen1884 | Phase II | Cervical Cancer | Active Not Recruiting | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer | Mar 19, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Agenus Inc. (DE:AJ8) have in its pipeline
Agenus DE:AJ8 is currently developing the following drugs: Zalifrelimab, Evofosfamide, Balstilimab, Gemcitabine, Nab-paclitaxel, Botensilimab, Standard of Care, Botensilimab, Balstilimab, Botensilimab, Balstilimab, Botensilimab, Balstilimab, Agen1571, Agen2034, Cr6086, Agen1777, A Pd-1 Inhibitor, Gemcitabine, Nab Paclitaxel, Nlm-001, Zalifrelimab, Botensilimab, Agen2373, Agen2034, Agen1884, Agen2034, Zalifrelimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.